Exciting Additions to Distinguished Scientific Advisory Board
One of the many rewarding aspects of my position as
the CDI’s scientific director is my collaboration with
the Institute’s Scientific Advisory Board. Consisting of
internationally recognized science leaders, this six-person
board oversees our research initiatives through review and
recommendation of grant awards. I’d like to introduce two
of the newest advisory board members who now lend their
knowledgeable perspectives to the CDI.
Aaron DiAntonio, MD, PhD, professor of developmental
biology at Washington University School of Medicine,
attended Stanford University School of Medicine. There,
he studied the molecular mechanisms of synaptic
transmission, the process by which one neuron
communicates with another neuron, such as a muscle
cell, at a connection point or synapse. He completed
postdoctoral training at the University of California,
Berkeley, in the area of neural development.
Dr. DiAntonio is a leading investigator on the development,
maintenance and regeneration of axons and synapses.
His studies have identified important molecular pathways
that control neural development and neuro-degeneration,
which could be potential therapeutic targets in many
Sam Klein, MD, William H. Danforth Professor of
Medicine and Nutritional Science, and chief of the
Division of Geriatrics and Nutritional Science at the
School of Medicine’s Department of Medicine, brings to
the Scientific Advisory Board internationally recognized
expertise in lipid metabolism in obesity and risks for
diabetes and cardiovascular disease.
Dr. Klein graduated from Temple University Medical
School and subsequently obtained a master’s degree
in nutritional biochemistry and metabolism from
Massachusetts Institute of Technology. Dr. Klein completed
his internship and residency training in internal medicine
and a clinical fellowship in nutrition at University Hospital
in Boston. Additional training included research and
clinical fellowships in nutrition and metabolism and in
gastroenterology at Harvard Medical School and Mount
Sinai Hospital in New York. Dr. Klein’s research seeks to
understand the mechanisms responsible for metabolic
dysfunction associated with weight gain and obesity.
To a great degree, the Scientific Advisory Board provides
the navigation necessary to steer the CDI into the future
and ensure its leadership in pediatric research. Given their
stellar backgrounds, I’m confident Drs. DiAntonio and Klein
will add knowledgeable hands to the wheel.